<i>Salmonella</i>-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma.

ABSTRACT:

Background

Although immune checkpoint inhibitor (ICI)-based therapy is advantageous for patients with advanced melanoma, resistance and relapse are frequent. Thus, it is crucial to identify effective drug combinations and develop new therapies for the treatment of melanoma. SGN1, a genetically modified Salmonella typhimurium species that causes the targeted deprivation of methionine in tumor tissues, is currently under investigation in clinical trials. However, the inhibitory effect of SGN1 on melanoma and the benefits of SGN1 in combination with ICIs remain largely unexplored. Therefore, this study aims to investigate the antitumor potential of SGN1, and its ability to enhance the efficacy of antibody-based programmed cell death-ligand 1 (PD-L1) inhibitors in the treatment

SUBMITTER: Zhou S 

PROVIDER: S-EPMC10836381 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature